Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23464918 | 0.84 | — | — | |
| SCHEMBL3009879 | 0.82 | SMN1; SMN2 (0.67) | SMN1; SMN2PKMCYP1A2CYP2C9CYP2D6 | |
| SCHEMBL23331595 | 0.82 | SMN1; SMN2 (0.67) | SMN1; SMN2PKMCYP1A2CYP2C9CYP2D6 | |
| SCHEMBL3120355 | 0.80 | SMN1; SMN2 (0.64) | SMN1; SMN2PKMCYP1A2CYP2C9CYP2D6 | |
| SCHEMBL18129500 | 0.79 | SMN1; SMN2 (0.49) | SMN1; SMN2PKMCYP1A2CYP2C9CYP2D6 | |
| SCHEMBL13965465 | 0.78 | SMN1; SMN2 (0.56) | SMN1; SMN2PKMCYP1A2CYP2C9CYP2D6 | |
| SCHEMBL805882 | 0.77 | PKM (0.60) | SMN1; SMN2PKMCYP1A2CYP2C9CYP2D6 | |
| SCHEMBL12448163 | 0.77 | SMN1; SMN2 (0.60) | SMN1; SMN2PKMCYP1A2CYP2C9CYP2D6 | |
| SCHEMBL14934343 | 0.77 | SMN1; SMN2 (0.60) | SMN1; SMN2PKMCYP1A2CYP2C9CYP2D6 | |
| SCHEMBL4030616 | 0.76 | POLB (0.68) | SMN1; SMN2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2380881-B1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2017-01-25 | — | — | EP | disclosed |
| US-20130303535-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | Sumitomo Pharma Co., Ltd. (JP) | 2013-11-14 | — | — | US | disclosed |
| US-8575153-B2 | Pyridine-3-carboxyamide derivative | KOWA COMPANY, LTD. (JP) | 2013-11-05 | — | — | US | disclosed |
| US-8471038-B2 | Bicyclic heterocyclic compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20110294804-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-12-01 | — | — | US | disclosed |
| EP-2380877-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | Kowa Company, Ltd. (JP) | 2011-10-26 | — | — | EP | disclosed |
| EP-2380881-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-20110237590-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | KOWA COMPANY, LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| US-7943609-B2 | Such as (tetrahydr)imidazo(4,5-c ) quinoline or naphthymidine; immunomoderators; induce cytokine biosynthesis in animals; anticancer agents; viricides | 3M INNOVATIVE PROPRERTIES COMPANY (US) | 2011-05-17 | — | — | US | disclosed |
| US-20090270443-A1 | 1-AMINO IMIDAZO-CONTAINING COMPOUNDS AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20080269192-A1 | Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| WO-2006026760-A2 | 1-AMINO IMIDAZO-CONTAINING COMPOUNDS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294804-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | OPRL1, SCN1B, OPRD1 | SMN1; SMN2 81/4885PKM 4448/4885CYP1A2 3440/4885 |
| US-20080269192-A1 | Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds | IFNAR1, IFNG, IL4 | SMN1; SMN2 2992/4885PKM 4315/4885CYP1A2 802/4885 |
| US-20130303535-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | OPRL1, SCN1B, OPRD1 | SMN1; SMN2 81/4885PKM 4448/4885CYP1A2 3440/4885 |
| US-20090270443-A1 | 1-AMINO IMIDAZO-CONTAINING COMPOUNDS AND METHODS | IL2, IL4I1, IFNG | SMN1; SMN2 3231/4885PKM 3230/4885CYP1A2 1975/4885 |
| US-20110237590-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | JAK3, JAK1, UACA | SMN1; SMN2 4406/4885PKM 4637/4885CYP1A2 2971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.